Afatinib D6 is the hexa-deuterated form of Afatinib (BIBW-2992; Gilotrif), which is an orally bioavailable dual (EGFR/ErbB) receptor tyrosine kinase (RTK) inhibitor approved by FDA as an anticancer drug to treat non-small cell lung carcinoma (NSCLC).

纯度：≥98%

CAS：1313874-96-2